A Phase 1 interventional study of Enlicitide Decanoate and Atorvastatin in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn what happens to enlicitide decanoate and atorvastatin in a healthy person's body over time. Researchers want to learn what happens to enlicitide decanoate in the body when it is given with and without another medicine called atorvastatin and what happens to atorvastatin in the body when it is given with or without enlicitide decanoate.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive a single oral dose of atorvastatin (Treatment A) on Day 1.
Drug: Atorvastatin
Participants receive a single oral dose of enlicitide decanoate plus a single oral dose of atorvastatin (Treatment B) on Day 1.
Drug: Enlicitide Decanoate · Drug: Atorvastatin
Participants receive a single oral dose of enlicitide decanoate (Treatment C) on Day 1.
Drug: Enlicitide Decanoate
Oral administration
Oral administration
Also known as: Lipitor
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Atorvastatin and its Metabolites
Blood samples will be collected to determine the AUC0-Inf of atorvastatin and its metabolites.
Time frame: At designated timepoints (up to approximately 8 days)
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Atorvastatin and its Metabolites
Blood samples will be collected to determine the AUC0-Last of atorvastatin and its metabolites.
Time frame: At designated timepoints (up to approximately 8 days)
Maximum Plasma Concentration (Cmax) of Atorvastatin and its Metabolites
Blood samples will be collected to determine the Cmax of atorvastatin and its metabolites.
Time frame: At designated timepoints (up to approximately 8 days)
Time to Maximum Plasma Concentration (Tmax) of Atorvastatin and its Metabolites
Blood samples will be collected to determine the Tmax of atorvastatin and its metabolites.
Time frame: At designated timepoints (up to approximately 8 days)
Apparent Terminal Half-Life (t1/2) of Atorvastatin and its Metabolites
Blood samples will be collected to determine the t1/2 of atorvastatin and its metabolites.
Time frame: At designated timepoints (up to approximately 8 days)
Apparent Clearance (CL/F) of Atorvastatin
Blood samples will be collected to determine the CL/F of atorvastatin.
Time frame: At designated timepoints (up to approximately 8 days)
Apparent Volume of Distribution (Vz/F) of Atorvastatin
Blood samples will be collected to determine the Vz/F of atorvastatin.
Time frame: At designated timepoints (up to approximately 8 days)
Area Under the Concentration-Time Curve from Time 0 to 24 Hours (AUC0-24hrs) of Enlicitide Decanoate
Blood samples will be collected to determine the AUC0-24hrs of enlicitide decanoate.
Time frame: At designated timepoints (up to approximately 24 hours)
Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Enlicitide Decanoate
Blood samples will be collected to determine the AUC0-Inf of enlicitide decanoate.
Time frame: At designated timepoints (up to approximately 8 days)
Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Enlicitide Decanoate
Blood samples will be collected to determine the AUC0-Last of enlicitide decanoate.
Time frame: At designated timepoints (up to approximately 8 days)
Maximum Plasma Concentration (Cmax) of Enlicitide Decanoate
Blood samples will be collected to determine the Cmax of enlicitide decanoate.
Time frame: At designated timepoints (up to approximately 8 days)
Time to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate
Blood samples will be collected to determine the Tmax of enlicitide decanoate.
Time frame: At designated timepoints (up to approximately 8 days)
Apparent Terminal Half-Life (t1/2) of Enlicitide Decanoate
Blood samples will be collected to determine the t1/2 of enlicitide decanoate.
Time frame: At designated timepoints (up to approximately 8 days)
Apparent Clearance (CL/F) of Enlicitide Decanoate
Blood samples will be collected to determine the CL/F of enlicitide decanoate.
Time frame: At designated timepoints (up to approximately 8 days)
Apparent Volume of Distribution (Vz/F) of Enlicitide Decanoate
Blood samples will be collected to determine the Vz/F of enlicitide decanoate.
Time frame: At designated timepoints (up to approximately 8 days)
Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 10 weeks
Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 6 weeks
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Nov 2023 to primary completion in Dec 2023, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MK-0616 · Atorvastatin